



June 30, 2017

Company name: Mitsubishi Tanabe Pharma Corporation
Representative: Masayuki Mitsuka
President and Representative Director
Code number: 4508, First Section, Tokyo Stock Exchange
Contact: Yoshifumi Mifune, General Manager,
Corporate Communications Department
TEL: +81-6-6205-5211

Conclusion of Agreement on Absorption-Type Company Split of Generic Drugs and Part of the Long-Listed Products Business

Mitsubishi Tanabe Pharma Corporation (hereinafter “MTPC”) resolved at its Board of Directors meeting held today that it will conclude an agreement on an absorption-type company split as planned that will have Tanabe Seiyaku Hanbai Co., Ltd. (Head office: Chuo-ku, Osaka; President & Representative Director: Masao Hatta; hereinafter “TSH”) succeed all of the marketing rights including manufacture and sales approval, contract of manufacturing, related agreements such as a joint development agreement, inventory, trademarks, copyright, and safety management information for MTPC’s business of generic drugs and part of long-listed products that was published in the announcement “Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of Subsidiary” dated March 28, 2017.

As TSH is a wholly-owned subsidiary of MTPC, there will be no delivery of compensation from TSH to MTPC upon the company split.

Going forward, all of TSH shares held by MTPC will be transferred to Nipro Corporation (Head office: Kita-ku, Osaka; President & Representative Director: Yoshihiko Sano; hereinafter “Nipro”) on October 1, 2017.

Schedule of the company split and transfer of shares

Date of conclusion of the agreement of transfer of shares	March 28, 2017
Date of conclusion of the agreement of absorption-type company split	July 1, 2017
Effective date of the absorption-type company split	October 1, 2017 (planned)
Closing date of the transfer of shares	October 1, 2017 (planned)

End